| 1 |
30542809 | Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine. | 2019 Feb |
1 |
| 2 |
29995258 | Virtual Thorough QT (TQT) Trial-Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation Using Multi-Scale Physiologically Based Ventricular Cell-wall Model Exemplified with Tolterodine and Fesoterodine. | 2018 Jul 11 |
1 |
| 3 |
29128914 | Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study. | 2017 Nov |
1 |
| 4 |
23497983 | Fesoterodine, its active metabolite, and tolterodine bind selectively to muscarinic receptors in human bladder mucosa and detrusor muscle. | 2013 Apr |
1 |
| 5 |
21352267 | Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. | 2011 Aug |
7 |
| 6 |
19145494 | The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. | 2009 Mar 7 |
1 |
| 7 |
19835561 | The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. | 2009 |
2 |
| 8 |
19956551 | Fesoterodine for the treatment of urinary incontinence and overactive bladder. | 2009 |
2 |